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Chronic alpha-1 -adrenergic blockade increases 
sympathoneural but not adrenomedullary 
activity in patients with essential hypertension
Marie-Cécile Jacobs, Jacques W.M. Lenders, 
Jacques J. Willemsen* and Theo Thien
Objective: Doxazosin, a selective a]-adrenoceptor antagonist, lowers blood pressure 
by reducing peripheral vascular resistance without causing reflex tachycardia. To 
discover whether antihypertensive treatment with an aj -adrenoceptor blocker is 
accompanied by an increase in sympathoadrenomedullary activity, we studied plasma 
catecholamine kinetics before and during treatment with doxazosin.
Patients and methods: Eleven patients with essential hypertension were studied before 
and after 3 months' treatment with doxazosin (4-8 mg a day). 3H-noradrenaline and 
3H-adrenaline were infused simultaneously and blood samples were collected to 
calculate plasma catecholamine kinetics before and during sympatho-adrenomedul- 
lary stimulation (lower-body negative pressure).
Results: Doxazosin decreased systolic and diastolic blood pressure and forearm 
vascular resistance, whereas the heart rate did not change significantly. During 
doxazosin, baseline arterial plasma noradrenaline increased from 0.97±0.07 to
1.21 ± 0 .0 7 nmol/l, and this appeared to be due to an increase in total body 
noradrenaline spillover from 1.54±0.15 to 1.84 + 0 .1 6 nmol/min; noradrenaline 
clearance did not change significantly. Forearm noradrenaline spillover also 
increased, from 0 .89±0.18  to 1.48±0.23 pmol/10 0 ml per min. In contrast, arterial 
plasma adrenaline, total body adrenaline spillover and adrenaline clearance were not 
significantly affected by doxazosin treatment. The response of plasma noradrenaline 
and total body and forearm spillover of noradrenaline to lower-body negative pressure 
(—40 mmHg) was significantly increased during doxazosin administration, whereas the 
response of the adrenaline kinetic parameters were not altered.
Conclusions: The blood pressure reduction induced by a chronic administration 
of the -adrenoceptor blocker doxazosin elicits a baroreceptor-mediated reflexive 
increase in sympathoneural but not in adrenomedullary activity. The latter finding 
might partly explain why the heart rate is not increased during chronic treatment with 
this a ]-adrenoceptor blocking drug.
Journal of Hypertension 1995, 13:1837-1841 
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Introduction
Doxrazosin is a selective Cti-adrenoceptor blocking drug 
with a slow onset o f  action; it lowers blood pressure by 
decreasing systemic vascular resistance [1,2]. In contrast 
to the acute administration o f  CCi -adrenoceptor blockers, 
chronic administration in hypertensive patients does not
elicit a reflexive increase in the heart rate. This suggests 
that baro re flex-mediated sympathetic activity is not 
increased during chronic treatment with doxazosin. The 
lack o f  reflex tachycardia has also been attributed to the 
absence o f an interruption o f  the presynaptic inhibitory 
effect by noradrenaline upon neuronal noradrenaline 
release [3]. Central CC|-adrenoceptor antagonism has
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been suggested as an alternative mechanism for the 
absence o f reflex tachycardia [4]. However, treatment 
with prazosin, a similar CL] -adrenoceptor blocker to 
doxazosin but with a rapid onset of action, induces 
an increase in plasma levels of noradrenaline [5-7]. 
Although it has been assumed that the increased 
plasma noradrenaline levels are caused by an increase in 
baroreflex-mediated sympathetic activity, no definitive 
explanation is available for the increase in plasma 
noradenaline levels. Elevated plasma noradrenaline levels 
might be due to a reflexive increase in sympathoneuronal 
release o f noradrenaline or to a reduced clearance o f  
noradrenaline.
The main objective o f the present study was to 
assess the effects of a chronic blood pressure reduction 
induced by the CXi -adrenoceptor blocker doxazosin 
on the baroreflex-mediated activity of the sympatho- 
adrenomedullary system. For this purpose, we used the 
isotope dilution method with a steady-state infusion o f 
tritiated catecholamines [8]. Before and after chronic 
doxazosin treatment (3 months), spillover and clearance 
o f noradrenaline and adrenaline were assessed in essential 
hypertensives and this was examined before and during 
stimulation o f  the sympatho-adrenomedullary system by 
two different intensities o f  lower-body negative pressure.
Subjects and methods
Subjects
Eleven subjects with essential hypertension (m ean±SD  
age 35.8 + 2.3 years) participated in the study. Before 
entry all participants had a normal physical examination 
and none were found to suffer from cardiovascular or 
other diseases. Secondary hypertension was excluded 
according to standard clinical criteria, and all subjects had 
a normal renal function. The m ean±SD Quetelet index 
was 23.6 ± 0 .7  kg/m 2. Antihypertensive treatment was 
withdrawn at least 4 weeks before the study; after it was 
withdrawn, blood pressure was measured three times at 
2-week intervals. The m e a n iS D  basal systolic/diastolic 
blood pressure before treatment with doxazosin was 
1 4 7 ± 3 /9 5 ± 2 m m H g  and the heart rate was 77 ± 3  
beats/min. All subjects gave written informed consent 
and the study protocol was approved by the Hospital 
Ethics Committee.
Study protocol
All patients were studied twice: before and after 
treatment with doxazosin for 3 months. Each patient 
started with doxazosin at 2 mg once a day and blood 
pressure was monitored every 3 weeks. The dose was 
increased every 3 weeks by 2 mg to a maximum of 8 mg 
a day unless diastolic blood pressure had fallen by at least 
25% on  the current dose. Patients with a sufficient blood 
pressure fall remained on the titrated dose until the end 
o f the 3-m onth period. After 3 months, two patients
were taking 4 mg a day, one was taking 6 mg a day and 
nine were taking 8 mg doxazosin a day.
O n each study day, the subjects were allowed a light 
breakfast. All were required to abstain from alcohol, 
nicotine and caffeinated foods and beverages for at least 
24 h before each study day. All studies were carried out 
in the m orning in a room with constant temperature. 
During the study the subjects remained supine in 
a lower-body negative pressure box that was used 
to stimulate sympatho-adrenomedullary activity. After 
instrumentation, radiotracer infusions (see below) were 
started and the subjects rested for 30m in . D uring the 
last 3 min, baseline recordings o f  blood pressure, heart 
rate and nine forarin blood flow curves were obtained. 
Then arterial and venous blood samples were drawn 
simultaneously to determine plasma concentrations of 
endogenous and tritiated catecholamines.
Thereafter, lower-body negative pressure was applied at 
- IS m m H g  for 15 min. Blood pressure, heart rate and 
forearm blood flow recordings and blood samples were 
collected in sequence beginning after 12 min o f  lower- 
body negative pressure. A rest period o f  30 min ensued 
and then another 15 min o f lower-body negative pressure 
at -4 0 m m H g  was applied, and blood pressure, heart rate 
and forearm blood flow recordings and blood samples 
were obtained as before.
Procedures
A brachial artery was cannulated to m onitor blood 
pressure and the heart rate (Hewlett-Packard GmbH, 
Böblingen, Germany) and to draw arterial blood 
samples. An intravenous catheter was inserted into a 
deep brachial vein in the ipsilateral arm for collecting 
venous blood samples. A forearm venous catheter in 
the contralateral arm was used for simultaneous infusion 
of 3H-noradrenaline and 3H-adrenaline. Forearm blood 
flow was recorded by venous occlusion strain-gauge 
plethysmography with air-filled cuffs [9]; during this 
measurement and while blood samples were drawn, the 
hand circulation was excluded by inflating a wrist cuff 
to lOOmmHg above systolic blood pressure [10].
To assess catecholamine kinetics, 3H-noradrenaline (L-
[O-2,5,6-3H]-noradrenaline) and 3H-adrenaline (L-[N-
methyl-^H]-adrenaline), with high specific activity, 
were infused intravenously. Tritiated catecholamines 
were obtained from D uPont N ew  England Nuclear 
(Hertogenbosch, the Netherlands), sterilized using a 
micropore filter (0.22 \im) and diluted in 0.9% NaCl 
containing acetic (0 .2 mol/l) and ascorbic (lm g/m l) 
acid. The aliquots were stored until used at -80°C for 
a maximum of 3 months. Sterilization, dilution and 
aliquoting were carried out under nitrogen. Just before 
use, an aliquot o f  each radiotracer was diluted in 0.9% 
NaCl.
After a bolus injection o f  each tracer at 15 ]U.Ci/m2, both 
tracers were infused continuously for 90 min at a rate of
0.35 |iC i/m 2 per min. The weights o f  the two syringes 
containing the radiotracers were measured before and
after the infusion to verify the infusion rate. Samples o f  
the infúsate were taken at the end o f the infusion and 
stored at -80° C until assayed.
Analytical methods
Blood samples were collected in prechilled tubes con­
taining ethyleneglycol-bis-(p-aminoethylether)-N,AiiV,J
jV-tetraacetic acid (0.25mol/l) and glutathione (0.2 
mol/1). T he blood samples were placed on melting 
ice. Plasma was separated by refrigerated centrifugation 
and frozen until assayed within 2 months o f collec­
tion. Plasma samples were analysed for concentrations 
o f  noradrenaline, adrenaline, 3H-noradrenaline and 
3H-adrenaline, using high-performance liquid chro­
matography w ith  fluorimetric detection after selective 
precolum n derivatization o f  the catecholamines with 
the fluorescent agent 1,2-diphenyle thy lene diamine [11]. 
Using a Gilson fraction collector, model 201-202, 
(Gilson Medical Electronics, Viüiers le Bel, France) 
connected to an automatic sample injector, Wisp 
710B, (Waters Associates, Milford, Massachusetts, USA), 
we collected 3H-noradrenaline and 3H-adrenaline into 
scintillation vials for 1 min, starting at the beginning of 
the peaks o f  noradrenaline and adrenaline in the standard 
mixture.
Data analysis
Forearm vascular resistance was calculated by dividing 
mean arterial blood pressure by forearm blood flow and 
was expressed in  arbitrary units (AU). The average of 
the haemodynamic data during 3 min o f recording was 
calculated.
The clearance o f  noradrenaline from arterial plasma 
was calculated by dividing the rate o f  3H-noradrenaline 
infusion by the steady-state arterial plasma concen­
tration o f  3H-noradrenaline. Total body noradrenaline 
spillover, the estimated rate o f  appearance of endogenous 
noradrenaline in arterial plasma, was calculated by 
multiplying the steady-state arterial plasma noradrenaline 
concentration by the clearance. Analogously, nora­
drenaline spillover in the forearm (S, pm ol/m in per 
100 nil), was estimated as:
S =  P N af+  [P(NV- N a)]
where P is forearm plasma flow, N a is arterial plasma 
noradenaline, N v is venous plasma noradrenaline and:
f= (3H-Na ~3H-Nv)/3H-Na
The function f  represents the fractional extraction o f 
the tracer in the forearm. The forearm plasma flow, 
in units o f n il/m in /100  ml, was calculated from the 
forearm blood flow and haematocrit. The clearance o f 
noradrenaline in the forearm (ml/min per 100 ml) was 
calculated by multiplying the forearm plasma flow by the 
function f.
The clearance o f adrenaline from arterial plasma and the 
estimated rate o f  appearance o f endogenous adrenaline 
into arterial plasma were calculated according to similar
formulas.
Results are expressed as means ±SEM  unless indicated 
otherwise. To test the effects o f  doxazosin on baseline 
plasma kinetic variables, the Wilcoxon signed rank test 
was used. This test was also used to  test for the effects o f  
lower-body negative pressure on each variable. P < 0 .05  
(two-sided) was considered significant.
Results
Haemodynamic data
Doxazosin decreased systolic blood pressure from 147 ± 3  
to 13 5 ± 4 m m H g  and diastolic pressure from 95 ± 2  
to 8 5 ± 3 m m H g  (P<0.05). The heart rate decreased 
slightly, from 77 ± 3  to 70 ± 2  beats/min, bu t this was 
not significant. Forearm vascular resistance decreased 
significantly (P<0.05), from 89 ± 7  to 64 ± 6  AU.
Doxazosin had no effect on the blood pressure and 
heart rate response to a lower-body negative pressure o f  
—IS m m H g but the increase in forearm vascular resis­
tance during lower-body negative pressure at —15 m m H g 
was smaller after doxazosin treatment (+7 ±  2 AU) than 
before (+ 31+ 8A U , P<0.05). T he  blood pressure and 
heart rate responses to lower-body negative pressure 
at —40 m m H g were also unaffected by doxazosin, 
but the increase in forearm vascular resistance was 
again significantly smaller after doxazosin treatment
(+5 ± 2 AU) than before (+32 ± 9 AU, P <  0.05).
Plasma noradrenaline kinetics
After treatment w ith doxazosin, all subjects had an 
approximately 20% higher plasma noradrenaline level 
than before (Table 1). This increase in arterial plasma 
noradrenaline appeared to be due to an increase in total 
body noradrenaline spillover of about 20% (Fig. 1), since 
total body clearance o f  noradrenaline was no t signifi­
cantly altered (Table 1). Forearm noradrenaline spillover 
was also significantly increased after doxazosin treatment 
(Fig. 1) while the local clearance o f  noradrenaline by the 
forearm was not significantly affected (Table 1).
The changes in plasma noradrenaline, total body and 
forearm noradrenaline spillover and total body and fore­
arm noradrenaline clearance in response to lower-body 
negative pressure (—15 mmHg) were not affected by 
doxazosin. However, with -4 0  m m H g lower-body neg­
ative pressure, the increase in plasma noradrenaline was 
significantly larger after doxazosin (+1.33 ±0.11 nmol/1) 
than before (+ 0 .8 8 ± 0 .1 0 nmol/1; P<0.05). Total body
and forearm noradrenaline spillover increases were also 
significantly higher during *-40 m m H g lower-body neg­
ative pressure after doxazosin treatment than before (Fig. 
2). The decreases in total body noradrenaline clearance 
during lower-body negative pressure at —40 m m H g were 
not significantly affected by doxazosin and the same 
applied to the reductions in forearm noradrenaline 
clearance (Fig. 2).
Table 1. Plasma levels and kinetics of noradrenaline and adrenaline 
before and after treatment with doxazosin.
Before After
doxazosin doxazosin
Noradrenaline
Arterial plasma level (nmol/I) 0.9710.07 1.21 ±0.07*
Total body spillover (nmol/l) 1.54 ±0.1 5 1.8410.16*
Total clearance (I/min) 1,57±0.10 1.52±0.09
Forearm spillover
(pmol/100ml per min) 0,89±0.1 8 1.48±0.23*
Forearm clearance
(ml/100 ml per min) 0.58 + 0.06 0.8210.10
Adrenaline
Arterial plasma level (nmol/l) 0.21 ±0.03 0.1510.02
Total body spillover (nmol/l) 0.42 + 0.07 0.2710.04
Total clearance (l/min) 1.94±0.10 1.81 ±0.11
Forearm clearance
(ml/100 ml per min) 0.70±0.07 0.89±0.12
*P<0.05 versus before doxazosin.
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Fig. 2. MeaniSEM arterial plasma noradrenaline (NA), total 
body (TSO) and forearm (FSO) spillover and total body (TCL) 
and forearm (FCL) clearance of noradrenaline in response to 
lower-body negative pressure at -40mmHg before (H) and 
after (P) doxazosin treatment.
Plasma adrenaline kinetics
After the administration o f  doxazosin, basal arterial 
plasma adrenaline was lower than before doxazosin 
treatment but the difference did not reach significance 
(Table 1). Total body adrenaline spillover was also 
lower after doxazosin but, again, the decrease was not 
significant. Total body clearance o f  adrenaline was not 
affected by doxazosin (Table 1).
The changes in adrenaline kinetics in response to lower- 
body negative pressure o f —15 and —40m m H g were not 
significantly altered by doxazosin.
Discussion
The main new finding o f  the present study is that long­
term antihypertensive treatment with the 0tj-adreno­
ceptor blocker doxazosin elicits a selective increase in 
sympathetic but not adrenomedullary activity. This was 
demonstrated by the increase in plasma noradrenaline 
and total body and forearm noradrenaline spillover with 
no concurrent increase in plasma levels and total body 
spillover o f adrenaline.
Chronic antihypertensive treatment with the -adreno­
ceptor blocker doxazosin resulted in a significant de­
crease in blood pressure and forearm vascular resistance. 
The heart rate did not increase, as shown previously 
for prazosin. The following three explanations for 
the unchanged heart rate have been put forward: 
vasodilation through 0Li-adrenoceptor blockade does 
not induce a reflexive increase in sympathetic activity 
because o f resetting of the arterial baroreceptor reflex; 
blockade o f  central Oti -adrenoceptors [4]; selective 
(Xj-adrenoceptor blocking drugs preserve the normal 
presynaptic (X2-adrenoceptor-mediated auto-ihhibition 
of neuronal noradrenaline release by noradrenaline [3].
However, in the present study plasma noradrenaline 
levels were increased, as were total body and forearm 
noradrenaline spillover. This is in accord with previous 
studies [5—7] on prazosin. An increase in the spillover 
of noradrenaline into the blood compartment can be 
caused by an increase in sympathetic nerve traffic, by 
a decrease in neuronal uptake o f  noradrenaline or by 
decreased inhibition o f  noradrenaline release through 
presynaptic 0t2-adrenoceptors. The last mechanism is 
unlikely to have occurred in the present study, since 
the affinity o f doxazosin for (X2-adrenoceptors is about 
400 times lower than that for a  j-adrenoceptors [12]. 
Alternatively, presynaptic a  j-adrenoceptors might be 
considered a possibility; however, although present in 
some species [13,14], no presynaptic CL\-adrenoceptors 
are functionally present in human blood vessels. Thus, 
an effect o f  doxazosin on presynaptic 0t2-adrenoceptors 
or on eventual presynaptic (X4-adrenoceptors has to be 
rejected as a possible explanation for the increase in 
noradrenaline spillover. The most likely explanation for 
the increase in noradrenaline spillover, both systemic ally
and in the forearm vascular bed, is that there was 
reflexive increase in sympathetic nerve traffic due to the 
blood pressure reduction. This argues strongly against 
a resetting o f  the arterial baroreceptor reflex during 
chronic treatment w ith doxazosin.
If there is, indeed, an increase in baroreflex-mediated 
sympathoneural activity during chronic aj-adrenoceptor 
blockade, then w hy is there no increase in the heart 
rate? Since cardiac Pi-adrenoceptors are equally sensitive 
to noradrenaline as to adrenaline in vitro, the increased 
noradrenaline spillover may be expected to elicit an 
increase in the heart rate. However, in vivo, noradrenaline 
usually induces a decrease in the heart rate because 
o f  the baroreflex-mediated increase in vagal nerve 
activity. An alternative explanation for the absence o f 
an increase in the heart rate could be provided by 
the absence o f  an increase in plasma adrenaline and in 
total body adrenaline spillover. Total body adrenaline 
spillover reflects a dre no medullary secretion o f adrenaline. 
Apparently, the blood pressure reduction induced by 
doxazosin does not stimulate adrenomedullary secretion 
o f  adrenaline but only the sympathoneuronal release of 
noradrenaline. This differentiated response to a reduction 
in blood pressure has also been described for other 
vasodilating antihypertensive drugs and is therefore not 
a specfic effect o f  a t-ad renocep to r blockers [15].
D uring  lower-body negative pressure at -40m m H g, 
both arterial and cardiopulmonary baroreceptors were 
de-activated and a marked increase in sympatho- 
adrenomedullary activity ensued, as illustrated by the 
increase in forearm vascular resistance, in plasma 
noradrenaline and forearm noradrenaline spillover and 
in total body noradrenaline and adrenaline spillover. 
D uring doxazosin treatment, the blood pressure and 
heart rate responses to lower-body negative pressure 
were not significantly altered but forearm vascular 
resistance response was lower than before doxazosin. 
This is at variance w ith a previous study with prazosin, 
demonstrating unaltered responses by peripheral vascular 
resistance to isometric exercise and exposure to cold 
[16],
Taken together, these data indicate that doxazosin 
is a very powerful a  j -adrenoceptor antagonist that 
blocks postsynaptic -adrenoceptors adequately, even 
during strong sympathetic stimulation. During chronic 
treatment w ith doxazosin there is a clear increase in 
baroreflex-mediated sympathoneural activity whereas 
adrenomedullary activity is not increased. This latter 
finding might provide a partial explanation for the
absence of an increase in the heart rate during chronic 
treatment with doxazosin.
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